# Exercise of Warrants and Issue of Equity

RNS Number : 3870D
Novacyt S.A.
18 February 2020

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

Exercise of Warrants and Issue of Equity

Paris, France and Camberley, UK - 18 February 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has received notice from Accent Grave BV of an exercise of warrants to subscribe for 1,000,000 new ordinary shares of €1/15 each in the capital of the Company ("Ordinary Shares") at a price of €1.16 per share for a total subscription of €1,160,000.

These warrants were transferred to Accent Grave BV from the vendors of Primerdesign Limited ("Primerdesign") who were issued with the warrants as part of the consideration for the sale of Primerdesign to Novacyt in May 2016.

Application will be made for 1,000,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective at 8.00 a.m. on or around 24 February 2020. Admission of the new Ordinary Shares to trading on Euronext is expected to occur on or before 24 February 2020.

Total Voting Rights

Following Admission, the total number of shares in the Company is 61,002,839. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company pursuant to Article L. 223-7 of the French Commercial Code and the Company's Articles. The Company is not subject to the disclosure guidance and transparency rules made by the Financial Conduct Authority under Part VI of FSMA.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

For further information, please refer to www.novacyt.com or contact:

Novacyt SA

Graham Mullis, Chief Executive Officer

Anthony Dyer, Chief Financial Officer

+44 (0)1276 600081

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

FTI Consulting (International)

Victoria Foster Mitchell / Mary Whittow

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com / mary.whittow@fticonsulting.com

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 47

arnaud.decheffontaines@fticonsulting.com

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high quality assays and reagents worldwide. The Group directly serves oncology, microbiology, haematology and serology markets as do its global partners, which include major corporates.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

IOEKKFBBABKDNBD